Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 10/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | LAP3 | P28838 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 2/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 3/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29469030 | 1.00 | LPL (0.42) | LPLLIPGANPEPLAP3JAK2 | |
| SCHEMBL31156286 | 0.84 | JAK2 (0.40) | LPLLIPGJAK2BTKAAK1 | |
| SCHEMBL16637594 | 0.84 | LPL (0.38) | LPLLIPGJAK2BTKAAK1 | |
| SCHEMBL4232484 | 0.83 | LPL (0.43) | LPLLIPGANPEPLAP3P4HB | |
| SCHEMBL31301038 | 0.83 | LPL (0.43) | LPLLIPGANPEPLAP3P4HB | |
| SCHEMBL29680508 | 0.82 | LPL (0.35) | LPLLIPGJAK2BTK | |
| SCHEMBL29036359 | 0.82 | LPL (0.37) | LPLLIPGANPEPLAP3 | |
| SCHEMBL29080160 | 0.82 | LPL (0.35) | LPLLIPGJAK2BTK | |
| SCHEMBL17618242 | 0.81 | LPL (0.42) | LPLLIPGANPEPLAP3P4HB | |
| SCHEMBL29486902 | 0.80 | LPL (0.41) | LPLLIPGANPEPLAP3P4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2024233605-A1 | COMPOUNDS AND THEIR USE AGAINST CANCER | TANGO THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-18 | — | — | US | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2007058989-A2 | QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-24 | — | — | WO | disclosed |
| EP-1784393-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20070093454-A1 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-26 | — | — | US | disclosed |
| US-20070093454-A1 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-26 | — | — | US | disclosed |
| US-20070093454-A1 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-26 | — | — | US | disclosed |
| WO-2006124865-A2 | BIARYLS DERIVATIVES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006124865-A2 | BIARYLS DERIVATIVES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006119451-A1 | PYRIMIDINES AND PYRAZINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006028904-A9 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006028904-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | FPR1, FPR2, FPR3 | LPL 1833/4885LIPG 1148/4885ANPEP 1488/4885 |
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | LPL 4166/4885LIPG 3534/4885ANPEP 3684/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | LPL 3982/4885LIPG 2426/4885ANPEP 4438/4885 |
| US-20070093454-A1 | Pyrimidines and pyrazines useful as modulators of ion channels | KCNJ1, KCNJ2, KCNJ11 | LPL 4189/4885LIPG 4330/4885ANPEP 4108/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | LPL 3923/4885LIPG 3144/4885ANPEP 3295/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | LPL 3841/4885LIPG 4084/4885ANPEP 1176/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | LPL 4181/4885LIPG 3541/4885ANPEP 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.